240 related articles for article (PubMed ID: 20498210)
1. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study.
Lanas A; Tornero J; Zamorano JL
Ann Rheum Dis; 2010 Aug; 69(8):1453-8. PubMed ID: 20498210
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
3. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
4. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
Rostom A; Moayyedi P; Hunt R;
Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
[TBL] [Abstract][Full Text] [Related]
5. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
Chan FK; Abraham NS; Scheiman JM; Laine L;
Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
[TBL] [Abstract][Full Text] [Related]
6. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
8. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients.
Wolfe F; Hawley DJ
J Rheumatol; 2000 Jul; 27(7):1668-73. PubMed ID: 10914849
[TBL] [Abstract][Full Text] [Related]
9. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis.
Lanas A; Garcia-Tell G; Armada B; Oteo-Alvaro A
BMC Med; 2011 Apr; 9():38. PubMed ID: 21489310
[TBL] [Abstract][Full Text] [Related]
10. Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.
Fries JF; Bruce B
J Rheumatol; 2003 Oct; 30(10):2226-33. PubMed ID: 14528521
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
[TBL] [Abstract][Full Text] [Related]
12. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
13. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study.
Sebaldt RJ; Petrie A; Goldsmith CH; Marentette MA
Am J Manag Care; 2004 Nov; 10(11 Pt 1):742-50. PubMed ID: 15623264
[TBL] [Abstract][Full Text] [Related]
14. Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks.
Chan FK
Nat Clin Pract Gastroenterol Hepatol; 2006 Oct; 3(10):563-73. PubMed ID: 17008926
[TBL] [Abstract][Full Text] [Related]
15. Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada.
Hartnell NR; Flanagan PS; MacKinnon NJ; Bakowsky VS
Am J Geriatr Pharmacother; 2004 Sep; 2(3):171-80. PubMed ID: 15561649
[TBL] [Abstract][Full Text] [Related]
16. GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin.
Pillai L; Burnett BP; Levy RM;
Curr Med Res Opin; 2010 May; 26(5):1055-63. PubMed ID: 20225990
[TBL] [Abstract][Full Text] [Related]
17. Management pattern for patients with osteoarthritis treated with traditional non-steroidal anti-inflammatory drugs in Spain prior to introduction of Coxibs.
Arboleya LR; de la Figuera E; Soledad García M; Aragón B;
Curr Med Res Opin; 2003; 19(4):278-87. PubMed ID: 12841920
[TBL] [Abstract][Full Text] [Related]
18. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population.
Rahme E; Pettitt D; LeLorier J
Arthritis Rheum; 2002 Nov; 46(11):3046-54. PubMed ID: 12428249
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
Dajani EZ; Islam K
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
[TBL] [Abstract][Full Text] [Related]
20. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib.
Steinfeld S; Bjørke PA
Rheumatology (Oxford); 2002 Apr; 41 Supp 1():23-7; discussion 35-42. PubMed ID: 12173277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
